Jason Luke
UPMC HIllman Cancer Center

Last Updated On 10/31/2024 4:26:39 PM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.

Employment
No Relationships to Disclose

Leadership
No Relationships to Disclose

Stock and Other Ownership Interests
Company: Actym Therapeutics
Recipient: You
Company: Pyxis
Recipient: You
Company: Tempest Therapeutics
Recipient: You
Company: Kanaph Therapeutics
Recipient: You
Company: Onc.AI
Recipient: You
Company: NeoTX
Recipient: You

Honoraria
No Relationships to Disclose

Consulting or Advisory Role
Company: Bristol-Myers Squibb
Recipient: You
Company: Merck
Recipient: You
Company: Novartis
Recipient: You
Company: Tempest Therapeutics
Recipient: You
Company: Alphamab Oncology
Recipient: You
Company: Abbvie
Recipient: You
Company: Bayer
Recipient: You
Company: Incyte
Recipient: You
Company: Werewolf
Recipient: You
Company: Regeneron
Recipient: You
Company: Xilio
Recipient: You
Company: Pfizer
Recipient: You
Company: Bright Peak
Recipient: You
Company: Onc.AI
Recipient: You
Company: Hotspot Therapeutics
Recipient: You

Speakers' Bureau
No Relationships to Disclose

Research Funding
Company: Merck
Recipient: Your Institution
Company: Bristol-Myers Squibb
Recipient: Your Institution
Company: Abbvie
Recipient: Your Institution
Company: Macrogenics
Recipient: Your Institution
Company: Astellas Pharma
Recipient: Your Institution
Company: Immatics
Recipient: Your Institution
Company: Moderna Therapeutics
Recipient: Your Institution
Company: Ikena Oncology
Recipient: Your Institution
Company: Numab
Recipient: Your Institution
Company: Takeda
Recipient: Your Institution
Company: Tizona Therapeutics, Inc.
Recipient: Your Institution

Patents, Royalties, Other Intellectual Property
Please describe: Serial #15/612,657 (Cancer Immunotherapy),
Recipient: You
Please describe: Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Recipient: You

Expert Testimony
No Relationships to Disclose

Travel, Accommodations, Expenses
Company: Merck
Recipient: You

Other Relationship
No Relationships to Disclose

(OPTIONAL) Uncompensated Relationships
not answered

(OPTIONAL) Open Payments Link
not answered